Skip to content

Inotuzumab ozogamicin

Besponsa (inotuzumab ozogamicin) is an antibody pharmaceutical. Inotuzumab ozogamicin was first approved as Besponsa on 2017-06-28. It is used to treat precursor cell lymphoblastic leukemia-lymphoma in the USA. It has been approved in Europe to treat precursor cell lymphoblastic leukemia-lymphoma. The pharmaceutical is active against B-cell receptor CD22.
Trade Name Besponsa
Common Name Inotuzumab ozogamicin
Indication precursor cell lymphoblastic leukemia-lymphoma
Drug Class Monoclonal antibodies: humanized, tumors as target; antibiotics (Micromonospora strains)
Inotuzumab ozogamicin
Get full access now